GnRH antagonists in IVF

Reproductive BioMedicine Online

Volumn 10, Issue 6, 2005, Pages 705-712

  Kolibianakis, Efstratios M ^a   Tarlatzis, Basil ^a   Devroey, Paul ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

Flexible antagonist administration; GnRH antagonists; Luteal support; Luteinizing hormone; Progesterone elevation

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

CLINICAL TRIAL; DOSE RESPONSE; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; LUTEINIZING HORMONE RELEASE; META ANALYSIS; MULTIPLE PREGNANCY; OOCYTE MATURATION; OVARY CYST; OVARY DISEASE; OVARY HYPERSTIMULATION; PHARMACOLOGICAL STIMULATION; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 20444395399     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61113-3     Document Type: Article

References (52)

1. Aboulghar MA, Mansour RT, Serour GI et al. 2004 Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reproductive BioMedicine Online 8, 524-527.
2. Akman MA, Erden HF, Tosun SB et al. 2001 Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Human Reproduction 16, 868-870.
3. Albano C, Grimbizis G, Smitz J et al. 1998 The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertility and Sterility 70, 357-359.
4. Albano C, Felberbaum RE, Smitz J et al. 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Human Reproduction 15, 526-531.
5. Al-Inany H, Aboulghar M 2001 Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database System Reviews: CD001750.
6. Beckers NG, Macklon NS, Eijkemans MJ et al. 2003 Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Journal of Clinical Endocrinology and Metabolism 88, 4186-4192.
7. Borm G, Mannaerts B 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Human Reproduction 15, 1490-1498.
8. Casan EM, Raga F, Polan ML 1999 GnRH mRNA and protein expression in human preimplantation embryos. Molecular Human Reproduction 5, 234-239.
9. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A et al. 2004 Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reproduction 19, 1979-1984.
10. D'Amato G, Caroppo E, Pasquadibisceglie A et al. 2004 A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. Fertility and Sterility 81, 1572-1577.
11. Daya S 2000 Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database System Reviews: CD001299.
12. Diedrich K, Diedrich C, Santos E et al. 1994 Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Human Reproduction 9, 788-791.
13. Escudero E, Bosch E, Crespo J et al. 2004 Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertility and Sterility 81, 562-566.
14. European and Middle East Orgalutran Study Group 2001 Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16, 644-651.
15. Fanchin R, Salomon L, Castelo-Branco A et al. 2003 Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction 18, 2698-2703.
16. Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S et al. 2003 Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. Journal of Assisted Reproduction and Genetics 20, 455-460.
17. Fauser BC, de Jong D, Olivennes F et al. 2002 Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 87, 709-715.
18. Fluker M, Grifo J, Leader A et al. 2001 Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 75, 38-45.
19. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 13, 3023-3031.
20. Griesinger G, Schultze-Mosgau A, Schroer A et al. 2004 GnRH agonist instead of hCG for final oocyte maturation in GnRH-antagonist cycles. Presented at the ESHRE Campus GnRH antagonists in IVF, Brussels, Abstracts, addendum 1-2.
21. Griesinger G, Schultze-Mosgau A, Dafopoulos K et al. 2005 Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Human Reproduction, in press.
22. Hughes EG, Fedorkow DM, Daya S et al. 1992 The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility 58, 888-896.
23. Karten MJ, Rivier JE 1986 Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocrine Review 7, 44-66.
24. Kiesel L, Runnebaum B 1992 Gonadotropin releasing hormone and analogs. Physiology and pharmacology. Gynakologisch-Geburtshilfliche Rundschau 32, 22-30.
25. Kol S, Lightman A, Hillensjo T et al. 1999 High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction 14, 2242-2244.
26. Kolibianakis E, Bourgain C, Albano C et al. 2002 Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertility and Sterility 78, 1025-1029.
27. Kolibianakis EM, Albano C, Kahn J et al. 2003a Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertility and Sterility 79, 873-880.
28. Kolibianakis EM, Albano C, Camus M et al. 2003b Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. Journal of Clinical Endocrinology and Metabolism 88, 5632-5637.
29. Kolibianakis EM, Bourgain C, Platteau P et al. 2003c Abnormal endometrial development occurs during the lineal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility 80, 464-466.
30. Kolibianakis EM, Zikopoulos K, Smitz J et al. 2004a Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Human Reproduction 19, 1525-1529.
31. Kolibianakis EM, Zikopoulos K, Smitz J et al. 2004b Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. Fertility and Sterility 82, 223-226.
32. Kolibianakis EM, Zikopoulos K, Schiettecatte J et al. 2004c Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Human Reproduction 19, 2490-2496.
33. Kolibianakis EM, Albano C, Camus M et al. 2004d Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility 82, 102-107.
34. Kolibianakis E, Albano C, Zikopoulos K et al. 2004e GnRH antagonists in poor responders. Acta Obstetricia et Gynecologica Scandinavica 83, 1216-1217.
35. Loumaye E 1990 The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Human Reproduction 5, 357-376.
36. Ludwig M, Katalinic A, Banz C et al. 2002 Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Human Reproduction 17, 2842-2845.
37. Mochtar MH 2004 The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. Human Reproduction 19, 1713-1718.
38. Nikolettos N, Al-Hasani S, Felberbaum R et al. 2001 Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. European Journal of Obstetrics, Gynecology, and Reproductive Biology 97, 202-207.
39. Olivennes F, Fanchin R, Bouchard P et al. 1994 The single or dual administration of the gonadotropin-releasing hormone antagonist cetrorelix in an in vitro fertilization-embryo transfer program. Fertility and Sterility 62, 468-476.
40. Olivennes F, Belaisch-Allart J, Emperaire JC et al. 2000 Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and Sterility 73, 314-320.
41. Ortmann O, Weiss JM, Diedrich K 2001 Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists. Human Reproduction 16, 608-611.
42. Out HJ, Rutherford A, Fleming R et al. 2004 A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction 19, 90-95.
43. Porter RN, Smith W, Craft IL et al. 1984 Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 2, 1284-1285.
44. Raga F, Casan EM, Kruessel J et al. 1999 The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 140, 3705-3712.
45. Simon C, Bellver J, Vidal C et al. 2004 Similar endometrial development in oocyte donors after daily treatment with high or low dose GnRH antagonist compared to GnRH agonists and natural cycles. Human Reproduction 19S, i93.
46. Smitz J, Ron-El R, Tarlatzis BC 1992 The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres. Human Reproduction 7 (suppl. 1), 49-66.
47. Tarlatzis BC, Bili H 2004 Safety of GnRH agonists and antagonists. Expert Opinion on Drug Safety 3, 39-46.
48. Tarlatzis BC, Kolibianakis EM 2002 Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Reproductive BioMedicine Online 5 (Suppl. 1), 8-13.
49. Tavaniotou A, Albano C, Smitz J et al. 2001 Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist cetrorelix. Human Reproduction 16, 663-667.
50. Vlaisavljevic, V, Reljic, M, Lovrec, VG, Kovacic, B. 2003 Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles - a prospective, randomized study. Reproductive BioMedicine Online 7, 301-308.
51. Westergaard L, Andersen Y, Humaidan P et al. 2004 Significant reduction of clinical pregnancy and implantation rates by use of GnRH agonist (Buserelin) as compared to hCG to induce ovulation in FSH/GnRH antagonists treated IVF/ICSI cycles. Human Reproduction 19, i3-i4.
52. Wikland M, Bergh C, Borg K et al. 2001 A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction 16, 1676-1681.